
Pfizer Is Making Moves On Cancer Data. Is It Now A Buy?
Pfizer (PFE)stock is butting up against its 200-day moving average after the company announced positive results for a combination of its drug, Padcev, with Merck's (MRK) Keytruda in patients with a form of bladder cancer. The companies tested their …